

## Special Issue

# Updates on Liver Cancer Management

### Message from the Guest Editor

Hepatocellular carcinoma (HCC) remains a significant global health burden due to its high incidence and mortality. Over the past few decades, significant progress has been achieved in the management of HCC, with advanced surgeries, including minimally invasive and robot-assisted procedures, liver transplantation, and local ablation therapy potentially offering a cure. Trans-arterial treatment techniques and radiation therapies are being developed further, while the recent introduction of immunotherapy opened a new systemic treatment landscape. The introduction of several classification system for HCC (such as BCLC), clearly defining patient groups and assigning reasonable treatment options, has standardized treatment. Currently, a comprehensive and multidisciplinary approach is crucial for the effective management of this disease. In this SI on **“Updates on Liver Cancer Management”** (including metastatic cancers), a comprehensive overview of the evolving management landscape and challenges to its improvements will be provided.

### Guest Editor

Prof. Dr. Zenichi Morise

Department of Surgery, School of Medicine, Fujita Health University  
Okazaki Medical Center, 1 Gotanda Harisakicho, Okazaki, Aichi 444-0827, Japan

### Deadline for manuscript submissions

1 October 2025



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/220546](https://mdpi.com/si/220546)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)